DUBLIN, Calif., May 31 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that Dr. Gregory Berk, Chief Medical Officer, and Dr. David Bearss, Vice President and Chief Scientist, will present at the OBR/INCE Oncology Pipeline Forum at 9 p.m. CDT on Saturday, June 2, 2007, at the House of Blues in Chicago.
Dr. Berk will present an overview of the Company’s clinical strategy, including information about its multi-targeted tyrosine kinase inhibitor, MP470. The Company recently received clearance from the FDA to initiate a Phase I clinical trial with MP470 in patients with advanced stage solid tumors. Dr. Bearss will discuss the Company’s CLIMB discovery process and its pipeline of targeted therapeutics and programs, including MP529, a late pre- clinical stage Aurora A inhibitor.
Downloadable presentation slides will be available on the SuperGen Web site at www.supergen.com beginning Saturday, June 2, 2007. Additionally, an archived audio webcast of the presentation will be available on the Oncology Business Review Web site at www.oncbiz.com beginning Wednesday, June 6, 2007.
About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com
Contacts: SuperGen SuperGen Timothy L. Enns Mary M. Vegh S.V.P., Corporate Communications Manager, Investor Relations & Business Development (925) 560-2845 (925) 560-0100 mary.vegh@supergen.comtenns@supergen.com
SuperGen, Inc.
CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment, +1-925-560-0100, tenns@supergen.com; or Mary M. Vegh, Manager,Investor Relations, +1-925-560-2845, mary.vegh@supergen.com, both ofSuperGen
Web site: http://www.supergen.com//
